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ABSTRACT 
Hyperlipidaemia is a metabolic disorder in population diagnosed by altered levels of Lipoproteins, 
Cholesterol and Triglycerides in plasma. This results deposition of lipids especially esterified cholesterol in 
the wall of arteries resulting in the narrowing and blockage of the arteries leading to heart diseases and 
other diseases such as cerebrovascular disease, renal disease, liver disease and peripheral vascular disease. 
The present work focused on comparative analysis of anti-hyperlipidaemic profile of Musta (Cyperus 
rotundus Linn.) in Male and female patients. The patients suffering from Hyperlipidaemia and its related 
disorders like non-insulin dependent diabetes etc. were divided into two groups, Group A confined to male 
and Group B confined to female. Each group contains 15 patients. All the patients were advised to take 3 gm 
powdered Musta rhizome in two or three divided doses for a period of 45 days. After treatment, Musta 
rhizome powder showed more significant anti-hyperlipidaemic activity in males than females. The 
significance in males total cholesterol (p<0.05), HDL (p<0.05), VLDL (p<0.05), triglycerides (p<0.05) is more 
than that of females VLDL (p>0.05), triglycerides (p>0.05). It is observed that in group A 40% patients got 
complete relief, 6.67 % patients got marked relief, 33.33% patients got moderate relief and 20 % patients 
got mild relief. Similarly, in group B patients 06.67% patients got complete relief, 6.67 % patients got 
marked relief, 53.33% patients got moderate relief and 33.33 % patients got mild relief. 
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INTRODUCTION 
 Ayurvedic medicine is existing on the earth for the 
welfare of the mankind. The worth of Ayurveda is to 
withstand the health of individual health and to cure the 
disease of a patient. The health is achieved by following the 
daily regimen, seasonal regimen, codes for healthy 
conduct, ethical regimen etc. Refusal to follow this regimen 
and conduct, individuals may be effected by diseases. 
Elevated levels of fats in the body is either due to lack of 
physical activities or some genetic factors or imbalanced 
diet. Addition of high quantity of fats in the food leads to 
Hyperlipidaemia or Abaddha Medo Vriddhi.  
Hyperlipidaemia is a metabolic condition in which 
the elevated levels of lipoproteins, cholesterol, 
triglycerides in plasma leads to thinning and obstruction of 
the arteries and other diseases such as CVD 
(cerebrovascular disease), cardiovascular disease, renal 
disease, liver disease peripheral and vascular disease. In 
Ayurvedic system of medicine, various herbal and mineral 
drugs such as Kapha hara and Medohara are useful for 
balancing dyslipidaemia.  
 Musta has been described in Vedas and Vedic texts. 
It is also described in Atharva parisistagrantha, Varaha 
srotasutra and Hiranyakesi srota sutra.[1] Musta is used in 
many simple and compound drug preparations to cure 
various diseases since time immemorial. Musta is having 
several dosage forms used internally as well as externally. 
For external application Musta can be used in the form of 
Taila and Ghrita (medicated vegetable oil and animal fat), 
Lepa (Topical application), Pradeha (Thick or Viscid 
ointment), Upanaha (Poultice), Pragharsha (Rubbing), 
Parisheka (Sprinkling/Showering of drug), Dhupana 
(fumigation) formulation. Musta can also be used 
internally using various forms like Kashaya (Decoction), 
Churna (Powder), Swarasa (fresh juice), Guti/Vati (Pills), 
Varti (Suppository), Kalka (Paste form), Lavana (Salt 
preparation), Kshara (Alkali form) and administered in 
various Karmas like Vasti (Enema), Nasya (Nasal drop), 
Gandusha (Gargling), Anjana (Collyrium). It can be used as 
food item in the form of Pramathya (dough prepared by 
boiling medicinal substances) and Paniya. Number of 
phytoconstituants such as -cyperone, cyperene, ß-selinine, 
Cyperenone, Luteolin, ß- sitosterol, Cyperotundone, 
Rotundone, Cyperolone, Cyperenone has been isolated and 
characterization from Musta plant.[2] Previous studies 
reported the pharmacological properties on lipid 
lowering,[3] infection diarrhoea,[4] antidaibetic & wound 
healing[5] and antioxidant activities[6] of Musta etc., There 
is no previous reports on comparative effect of 
antihyperlipidaemic activity of drug Musta (Cyperus 
rotundus Linn.) on male and female patients. Hence, 
present study evaluate the comparative effect of anti-
hyperlipidaemic activity of drug Musta (Cyperus rotundus 
Linn.) in male and female patients. 
MATERIALS AND METHODS 
Collection and Preparation of medicine 
 The experiment was conducted at the Department 
of Dravyaguna, S.V. Ayurvedic College/ Hospital, Tirupati.  
Musta rhizomes were purchased from Chennai 
market. These were then thoroughly cleaned with tap 
water followed by distilled water. The wiry, tough and 
slender roots were removed. About 10 kg of cleaned dried 
rhizomes were powdered in Pulverizer. The obtained 
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powder was sieved with mesh no. 100 to get fine powder. 
This powder was then tableted, each weighing 500mg.  
Selection of Patients 
The patients of hyperlipidaemia were selected based on 
following criteria. 
Inclusion criteria 
1. Persons suffering from hyperlipidaemia and its related 
disorders like non-insulin dependent diabetes in the 
age group of 30-60 years. 
2. Persons suffering from dyspnoea on exertion, weight 
gain, obesity, diabetes mellitus, hypertension and 
normal asymptomatic people were screened for 
hyperlipidaemia. 
3. As the hyperlipidaemic state is leading to many of the 
above said conditions, normal healthy patients were 
selected for the experimental trial. 
Exclusion criteria 
1. Patients below 30 years and above 60 years of age. 
2. Patients suffering from I.D.D.M. (Insulin- Dependent 
Diabetes Mellitus), severe diabetes mellitus with 
complications, malignant disorders and renal 
disorders. 
3. Patients who have the history of either cardiac or 
cerebral stroke and also who underwent by-pass 
surgery. 
Diagnostic criteria  
 Blood test for lipid profile, which includes total 
cholesterol, low density lipoprotein (LDL), high density 
lipoprotein (HDL), very low density lipoprotein (VLDL) 
and triglycerides was carried out before and after 
treatment for the evolution of hyperlipidaemia. Patients 
having abnormalities in one or more of the following 
criteria were considered as Hyperlipidaemia and were 
selected for the study. 
Table 1: Normal value of lipid profile(7) 
Total Cholesterol 
 < 200 → Desirable 
 200-239 → Borderline  
 ≥ 240 → High 
LDL 
 < 100 →Optimal 
 100-129 → Near optimal 
 130-159→ Borderline 
 160-189→ High 
 ≥ 190 → Very High 
VLDL 
 <32→ Desirable 
HDL 
 < 40 → Low 
 ≥ 60 → High 
 
Serum Triglycerides 
 < 150 → normal 
 150-199 → Borderline 
 200-499 → High 
 ≥ 500 → Very High 
Grouping 
30 patients of Hyperlipidaemia were selected and 
randomly divided into two groups, each consisting of 15 
patients based on the sex of the patient. 
1. Group - A: The patients of group A were confined to 
Males and advised to take Musta tablet.  
2. Group- B: The patients of group B were confined to 
Females advised to take Musta tablet. 
Duration of treatment 
The course of the treatment was fixed for 45 days. 
The patients were instructed to avoid diet which alters the 
lipid profile like oily food, butter, eggs, meat etc. 
Preliminary data was collected before treatment. 
Dose 
 Each patient under experimentation, was 
administered three grams of powdered Musta in a day 
three divided doses.  
Follow Up 
After completion of the treatment, the patients of 
both the groups were examined during follow up at an 
interval of two weeks for 45 days. 
Statistical analysis 
 The data according to parameters (lipid profile) 
were validated and subjected for statistical evaluation and 
significance of result is mentioned according to ‘P’ value. 
The overall result is mentioned according to percentage of 
relief and changes in number of parameters. If all the five 
parameters come within normal range, the result is 
considered as ‘Completely relieved’. If four parameters 
come within normal range, the result is considered as 
‘Markedly relieved’. If three parameters come within 
normal range, the result is considered as ‘Moderately 
relieved’. If two or only one parameter are within the 
normal range, the result is considered as ‘Mildly relieved’. 
If no parameter comes within the normal range, the result 
is considered as ‘Unchanged’. 
RESULTS 
The Observation of mean lipid profile parameter of 15 patients of each group are tabulated as under  
Table 2: Effect of medicine on lipid profile of group-A patients 
Parameters Mean (mg/dl) Mean  
diff. 
S.D. S.E. ‘t’ p Significance 
B.T. A.T B.T. A.T. B.T. A.T. 
T.C. 208.47 173.13 35.33 53.62 38.29 13.85 9.89 2.4166 <0.05 Statistically Significance 
L.D.L. 116.28 95.32 20.96 57.07 38.73 14.73 10.0 1.5333 >0.05 Not Statistically 
Significance 
H.D.L. 37.90 42.40 -4.5 6.96 5.60 1.78 1.44 2.5920 <0.05 Statistically Significance 
V.L.D.L. 54.22 35.42 18.80 28.18 14.93 7.27 3.85 3.8536 <0.05 Very Statistically 
Significance 
T.G. 274 183 91.0 143.98 86.64 37.17 22.37 3.7136 <0.05 Very Statistically 
Significance 
(n=15, df=14) 
The p value of four parameters were below 0.05, hence the result of treatment was significant. 
R.M. Kalpana, Bulusu Sitaram. A Clinical Study of Musta (Cyperus Rotundus Linn.) in Hyperlipidaemia  























Graph 1: Effect of medicine on lipid profile of group-A patients 
  
 
Table 3: Effect of medicine on lipid profile of group-B patients 
Parameters Mean (mg/dl) Mean  
diff. 
S.D. S.E. ‘t’ p Significance 
B.T. A.T B.T. A.T. B.T. A.T. 
T.C. 210.87 181.13 29.73 38.63 28.12 9.97 7.26 3.2600 <0.05 Very Statistically 
Significance 
L.D.L. 130.78 98.50 32.28 35.09 16.51 9.06 4.26 4.2636 <0.05 Extremely Statistically 
Significance 
H.D.L. 35.87 45.0 -9.13 6.17 7.84 1.59 2.02 3.9984 <0.05 Very Statistically 
Significance 
V.L.D.L. 46.02 37.69 8.33 24.82 16.36 6.40 4.22 1.3398 >0.05 Not Statistically 
Significance 
T.G. 2230.67 188.40 42.27 124.40 81.10 32.12 20.94 1.3556 >0.05 Not Statistically 
Significance 
(n=15, df=14) 
The p value of three parameters were below 0.05, hence the results of treatment was significant. 
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Table 4: Effect of medicine on lipid profile of group-A and group-B patients 
Parameters Mean (mg/dl) Mean  
diff. 
S.D. S.E. ‘t’ p Significance 
B.T. A.T B.T. A.T. B.T. A.T. 
T.C. 209.67 177.13 32.53 45.94 33.26 8.39 6.07 3.8355 <0.05 Extremely Statistically 
Significance 
L.D.L. 123.53 96.91 26.62 47.12 29.30 8.60 5.35 3.4350 <0.05 Very Statistically 
Significance 
H.D.L. 36.88 43.70 -6.81 6.54 6.82 1.19 1.24 4.6253 <0.05 Extremely Statistically 
Significance 
V.L.D.L. 50.12 36.56 13.56 26.42 15.43 4.82 2.81 3.3887 <0.05 Very Statistically 
Significance 
T.G. 252.33 185.70 66.63 134.03 82.50 24.47 15.06 3.3314 <0.05 Very Statistically 
Significance 
(n=30, df=28) 
The p value of all the parameters were below 0.05, hence the overall result of treatment was very significant. 


















OVERALL RESULT OF STUDY 
Table 5: Effect of medicine on group -A patients 
Assessment No. of Patients % of patients 
Completely Relieved 6 40 
Markedly Relieved 1 6.67 
Moderately Relieved 5 33.33 
Mildly Relieved 3 20 
Unchanged  0 0 
Out of 15 patients 40% patients got completely relief, 6.67 % patients got markedly relief, 33.33% patients got moderately 
relief and 20% patients got mildly relief. 
Table 6: Effect of medicine on group -B patients 
Assessment No. of Patients % of patients 
Completely Relieved 1 6.67 
Markedly Relieved 1 6.67 
Moderately Relieved 8 53.33 
Mildly Relieved 5 33.33 
















EFFECT OF MEDICINE ON LIPID PROFILE OF GROUP-A 
AND GROUP-B PATIENTS 
Mean (mg/dl)
Mean (mg/dl)
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GROUP-A 6 1 5 3 0













ASSESMENT OF EFFECT OF  MEDICINE ON GROUP A AND GROUP B
GROUP-A
GROUP-B
Out of 15 patients 06.67% patients got completely relief, 6.66 % patients got markedly relief, 53.33% patients got 
moderately relief and 33.33 % patients got mildly relief. 


















On assessment completely relieved patients (6) are more in Group-A, markedly relieved patients (1) were equivalent in 
both groups, moderately relieved patients (8) were more in Group-B, mildly relieved patients (5) were more in Group-B 
and there was no Unchanged patients in both groups. 
Table 7: Overall effect of medicine on group -A and group -B patients 
S.No Change in parameters % of relief 
GROUP A GROUP B 
1 Total cholesterol 16.94 14.09 
2 LDL 18.03 24.68 
3 HDL -11.87 -25.46 
4 VLDL 34.67 18.10 
5 Triglycerides  33.21 18.32 
(* negative sign in % of relief for HDL shows percentage of increase) 
Graph 5: overall result of the study according to % of relief 
 










CHOLESTROL LDL HDL VLDL TRIGLYCERIDES
Group-A 16.94 18.03 11.87 34.67 33.21








OVER ALL RESULT OF THE STUDY ACCORDING TO % OF RELIEF
Group-A
Group-B
Int. J. Ayur. Pharma Research, 2017;5(9):31-37 
     Available online at: http://ijapr.in  36 
Altered lipid profile markers particularly total cholesterol, triglycerides and decreased HDL cholesterol are signs 
for high risk of coronary heart disease. The patients with total mean cholesterol (208.47±13.85), triglycerides 
(274.0±37.17) and HDL (37.90±1.78) were advised to take 3 gm of powdered Musta in a day three divided doses. After 45 
days of treatment the decreased level of total mean cholesterol (173.13±9.89), triglycerides 183±22.37 and increased level 
of HDL (42.40±1.44) were recorded. These results showed that Musta is a drug of choice for the treatment of 
hyperlipidaemic patients. The comparative Observation of mean lipid profile parameter of 15 patients of group A, 15 
patients of group B and all patients in both groups are tabulated as under 
Table 8: Comparative effect of medicine on Lipid profile of Group- A, Group- B and Group A & B Patients 
Values are the mean ± Standard error, (Group A; n – 15), (Group B; n – 15), (Group A and B; n – 30), Symbols represent 
statistical significance. ***Extremely significance, **Very significance, * significance, ns -not significance. BT – Before 
treatment, AT – After treatment. 
DISCUSSION 
A clinical Study of Musta (Cyperus rotundus Linn.) 
in hyperlipidaemia patients showed significant result. 
Musta is considered to be effective as it could reduce the 
increased levels of serum cholesterol in both of the groups 
of patients. But comparatively the patients belonging to 
the male group exhibited a better response. 
Probable mode of action of drug 
Musta is a drug which has got Sita Virya and 
shows an independent action of Grahi and acts as Dipana 
and Pacana.[8] This type of peculiar action has got a 
significant action upon the Grahani, where it reduces the 
absorption of the fats consumed due to its Kashaya Rasa. 
Thus we can presume that Musta controls and regulates 
the fat metabolism. Due to its Laghu and Ruksha Gunas, it is 
balancing Baddhameda i.e., circulating lipids. 
Pharmacologically decoction of this tuber given orally to 
rats showed inhibition effect on gastric mobility and 
endogenous prostaglandins.[9] Whatever the drug that 
reduces the gastric motility to certain extent also shows its 
action upon the absorption of fats. 
Musta which is one of the important drugs of 
Vachadi Gana,[10] was taken as a trial drug to evaluate and 
to compare its anti hyperlipidaemic activity in males and 
females. Almost all Acharyas have mentioned Katu, Tikta, 
Kashaya Rasa; Laghu, Ruksha Guna; Sita Virya; Katu Vipaka 
for Musta.[2] 
 It is observed that in group A 40% patients got 
complete relief, 6.67 % patients got marked relief, 33.33% 
patients got moderate relief and 20 % patients got mild 
relief. Similarly, in group B patients 06.67% patients got 
complete relief, 6.67 % patients got marked relief, 53.33% 
patients got moderate relief and 33.33 % patients got mild 
relief. 
The total cholesterol level of group A patients was 
reduced by 16.94 %, while group B patients showed 14.09 
% reduction. The L.D.L. level of group A patients was 
reduced by 18.03 % while of group B patients was reduced 
by 24.68 %. The H.D.L. level of group A patients was 
increased by 11.87 % while of group B patients was 
increased by 25.46 %. The V.L.D.L. level of group A patients 
was reduced by 35.35% while of group B patients was 
reduced by 18.10%. The triglycerides level of group A 
patients was reduced by 33.21% while of group B patients 
was reduced by 18.32%. All the results were statistically 
significant (P<0.05) except LDL in Group-A, VLDL and 
Triglycerides in Group-B. 
Comparing the result of the both groups, it was 
observed that group A showed significant response than 
group B. it was even observed that the overall effects of the 
therapy showed significant results when both the groups 
are combined and evaluated statistically. 
CONCLUSION 
The results of this clinical study clearly showed 
that the phytoconstituents present in Cyperus rotundus 
rhizome have anti-hypolipidemic potentials. 
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